Aquacel Foam Adhesive Wound Dressing 10 x 10 cm Hydrofiber Technology 420680

Product Overview

Aquacel Foam Adhesive is a primary or secondary multi-layer foam dressing manufactured by ConvaTec, designed to manage low to moderate wound exudate while maintaining a moist wound environment that supports autolytic debridement and granulation. The defining feature is the integrated Hydrofiber™ wound-contact layer, composed of sodium carboxymethylcellulose (CMC) fibres that, on contact with exudate, transform into a soft, cohesive gel. This gel-locking action retains absorbed fluid within the dressing, reduces lateral wicking onto peri-wound skin, and contributes to maceration prevention — a recognised driver of delayed healing per EWMA (European Wound Management Association) consensus.

The dressing’s polyurethane foam core provides additional fluid handling capacity, while the silicone-free acrylic adhesive border secures the dressing without aggressive trauma to peri-wound skin on removal. The outer polyurethane film is waterproof and provides a viral and bacterial barrier of ≥25 nm, allowing the dressing to remain in place during showering. Aquacel Foam Adhesive may be left in place for up to 7 days depending on exudate level and clinician assessment, in line with TIME wound bed preparation principles and NICE NG19 (Diabetic foot problems) and NICE CG179 (Pressure ulcers) guidance.

Specifications

Clinical Indications

• Category I–III pressure injuries (pressure ulcers) per NPIAP/EPUAP/PPPIA Clinical Practice Guideline 2019
• Venous leg ulcers as primary or secondary dressing under graduated compression therapy
• Diabetic foot ulcers (Wagner Grade 1–2; Texas Class A1–A2) per IWGDF (International Working Group on the Diabetic Foot) 2023 guidelines and NICE NG19
• Post-surgical wounds (closed and dehisced incisions, donor sites, secondary intention healing)
• Superficial partial-thickness burns (≤10% TBSA in non-critical patients) per ISBI (International Society for Burn Injuries) practice guidelines
• Skin tears (ISTAP Type 1 and 2) per the International Skin Tear Advisory Panel framework
• Traumatic and abrasion wounds with low to moderate exudate

Frequently Asked Questions

Q: How does Aquacel Foam Adhesive differ from a standard polyurethane foam dressing (e.g. Mepilex Border, Allevyn)?
A: The clinical differentiator is the Hydrofiber™ wound-contact layer. Standard foam dressings absorb exudate into the foam matrix; Aquacel Foam adds a CMC layer that gels on contact and laterally locks fluid, reducing peri-wound maceration. This is documented in ConvaTec’s evidence portfolio and supports the dressing’s positioning for moderate-exudate diabetic foot ulcers and pressure injuries where peri-wound skin protection is critical.

Q: How often should the dressing be changed?
A: Change frequency is determined by exudate strikethrough, clinical signs of infection, and wound assessment — not by a fixed schedule. The dressing supports up to 7 days of wear under low-exudate conditions per the SmPC. NPIAP/EPUAP guidance recommends change “when exudate or strikethrough indicates,” with documentation each change.

Q: Can it be used on infected wounds?
A: Aquacel Foam Adhesive is not antimicrobial. For clinically infected wounds requiring topical antimicrobial cover, ConvaTec’s Aquacel Ag+ Foam (with ionic silver) is the indicated variant per IWII (International Wound Infection Institute) consensus on biofilm management. Aquacel Foam Adhesive (non-silver) may be used on non-infected wounds or in conjunction with systemic antibiotics where topical antimicrobial cover is not required.

Q: Is the dressing suitable for use under compression bandaging?
A: Yes. The dressing’s low profile and conformability make it suitable as a primary dressing under multi-component compression systems (e.g. Profore, Coban 2) for venous leg ulcer management per NICE CG168 and SVS/AVF clinical guidance.

Q: Is this product available with HSA Singapore registration?
A: Yes. Aquacel Foam Adhesive is registered with the Health Sciences Authority (HSA) Singapore as a Class B medical device. It also carries CE Mark under EU MDR 2017/745 and is manufactured to ISO 13485:2016 quality management standards with ISO 10993 biocompatibility testing.

References: NPIAP/EPUAP/PPPIA Clinical Practice Guideline 2019; IWGDF 2023 Guidelines on Diabetic Foot; NICE NG19 Diabetic foot problems; NICE CG179 Pressure ulcers; ISBI Practice Guidelines for Burn Care; ISTAP Skin Tear Classification; IWII Wound Infection in Clinical Practice 2022; WUWHS Consensus on moist wound healing; CE MDR 2017/745; ISO 13485:2016; ISO 10993 biocompatibility.